Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gynec and pediatricsProduct Categories: Analgesic, Anti-inflammatory, Anti-pyretic, Anthelmintic, Antibiotic, Anti-coagulant, Anti- platelet, Bleeding agents, Anti-fungal, Anti-hypertensive drugs, Anti malarial drugs, Cardiovascular System, Central Nervous System, Eye, Gastro-intestinal system, Hypoglycemic (Anti-diabetic), Multivitamin…
Mercury Laboratories has announced its 45th Annual General Meeting on Monday, September 28, 2026, to be held virtually. The company has provided remote e-voting for shareholders from September 24 to September 27, with September 21 as the cut-off date for eligibility. Share transfer books will be closed from September 22...
Mercury Laboratories has announced its 45th Annual General Meeting will be held via Video Conference/Other Audio Visual Means on September 28. Shareholders can participate remotely and cast votes electronically. The company’s Board has put forward a dividend of Rs. 3.5 per equity share for the financial year 2025-26. If approved...
Mercury Laboratories has announced a change in its Senior Management. Ms. Seema Salvi, the Head of Injectable Production, has resigned for better career opportunities. The company has appointed Mr. Sunil Sharma as the new Head of Injectable Production. Mr. Sharma, with a B.Pharm degree, brings over 19 years of experience...
Mercury Laboratories' Board proposed a dividend of Rs. 3.5 per share for FY2025-26, pending shareholder approval at the upcoming AGM. Dividend income is now taxable for shareholders, requiring the company to deduct tax at source. Shareholders must submit necessary documents for appropriate tax withholding, which varies by residential status. It's...
Mercury Laboratories has announced its financial results for the quarter. The company reported a total income from operations of ₹15.96 Cr. Net profit after tax for the period stood at ₹0.30 Cr. Earnings per share were ₹2.48. These unaudited results were reviewed by the Audit Committee and approved by the...
